Review: Targeting EZH2 in neuroblastoma
Authors:
Open Access
- 13 July 2023
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 119, 102600
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient OutcomeClinical Cancer Research, 2012
- EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1, CLU, RUNX3, and NGFRCancer Research, 2012
- The Polycomb complex PRC2 and its mark in lifeNature, 2011
- Outcome after Reduced Chemotherapy for Intermediate-Risk NeuroblastomaNew England Journal of Medicine, 2010
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center originNature Genetics, 2010
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylationMolecular Cancer Therapeutics, 2009
- EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiationProceedings of the National Academy of Sciences, 2009
- Ezh1 and Ezh2 Maintain Repressive Chromatin through Different MechanismsMolecular Cell, 2008
- Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 MethylationJournal of Biological Chemistry, 2008
- Substrate Preferences of the EZH2 Histone Methyltransferase ComplexJournal of Biological Chemistry, 2006